Form 4: Denali Therapeutics Director Steve Krognes Sells 30,000 Shares

Director Steve Krognes of Denali Therapeutics sold 30,000 shares of common stock on September 30, 2024, at a weighted average price of $29.03 per share.

Summary

• On September 30, 2024, Steve Krognes, a director of Denali Therapeutics Inc., sold 30,000 shares of common stock.
• The sale was executed at a weighted average price ranging from $28.50 to $29.32 per share.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2023.
• Following the transaction, Krognes directly owns 29,096 shares, including 13,467 unvested RSUs.
• He also indirectly owns 811,797 shares through The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, where he serves as trustee.
• 26,419 shares were allocated from the Steven Edward Krognes Revocable Trust to the Reporting Person.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by a company director. The sentiment is neutral as it simply reports a transaction without expressing any positive or negative outlook.

Industry Context

Insider sales are common and can be for a variety of reasons, including personal financial planning. It's important to consider the overall context of insider transactions, including the company's performance and industry trends.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, potentially leading to a slight decrease in investor confidence.

Key Dates